Información del artículo
Resumen
Staphylococcus aureus, agente causal más frecuente de las infecciones de piel y tejidos blandos (IPTB), ha experimentado en los últimos años un aumento de la resistencia a meticilina y un descenso de la sensibilidad a vancomicina. Daptomicina, por su espectro y actividad microbiológica, farmacocinética, experiencia clinica y seguridad parece un antibiótico muy apropiado en el tratamiento de las IPTB, sobre todo en las producidas por S. aureus resistente a meticilina.
Palabras clave:
Daptomicina
Staphylococcus aureus
Infección de piel y tejidos blandos
Abstract
In recent years, Staphylococcus aureus, the most commonly identified infectious agent causing skin and soft tissue infections (SSTIs), has shown an increase in methicillin resistance and decreased susceptibility to vancomycin. Because of its spectrum, microbiological activity, pharmacokinetics, and safety, as well as clinical experience in its use, daptomycin seems to be a highly appropriate antibiotic in the treatment of SSTIs, especially those produced by methicillin-resistant S. aureus.
Keywords:
Daptomycin
Staphylococcus aureus
Skin and soft tissue infections
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.S. Dryden.
Complicated skin and soft tissue infection.
J Antimicrob Chemother, 65 (2010), pp. iii35-iii44
[2.]
H.F.L. Wertheim, D.C. Melles, M.C. Vos, W. Van Leeuwen, A. Van Belkum, H.A. Verbrugh, et al.
The role of nasal carriage in Staphylococcus aureus infections.
Lancet Infect Dis, 5 (2005), pp. 751-762
[3.]
E.M. Begier, K. Frenette, N.L. Barrett, P. Mshar, S. Petit, D.J. Boxrud, et al.
A highmorbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns.
Clin Infect Dis, 39 (2004), pp. 1446-1453
[4.]
P. Koutkia, E. Mylonakis, J. Boyce.
Cellulitis: evaluation of possible predisposing factors in hospitalized patients.
Diagn Microbiol Infect Dis, 34 (1999), pp. 325-327
[5.]
G.J. Moet, R.N. Jones, D.J. Biedenbach, M.G. Stilwell, T.R. Fritsche.
Contemporary causes of skin and soft tissue infections in North America. Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004).
Diagn Microbiol Infect Dis, 57 (2007), pp. 7-13
[6.]
M.S. Dryden.
Skin and soft tissue infection: microbiology and epidemiology.
Intern J Antimicrob Agents, 34S1 (2009), pp. S2-S7
[7.]
M.J. DiNubile, B.A. Lipsky.
Complicated infections of skin and skin structures: when the infection is more than skin deep.
J Antimicrob Chemother, 53 (2004), pp. ii37-ii50
[8.]
D.C. Vinh, J.M. Embil.
Rapidly progressive soft tissue infections.
Lancet Infect Dis, 5 (2005), pp. 501-513
[9.]
J. Mensa, J. Barberan, P. Llinares, J.J. Picazo, E. Bouza, F. Álvarez Lerma, et al.
Guía de tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina.
Rev Esp Quimioter, 21 (2008), pp. 234-258
[10.]
J. Rodríguez-Baño, M.A. Domínguez, A. Blas Millán, C. Borraz, M. Pau González, B. Almirante, et al.
Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant Staphylococus aureus in Spain.
Clin Microbiol Infect, 15 (2009), pp. 1111-1118
[11.]
G.E. Schramm, J.A. Johnson, J.A. Doherty, S.T. Micek, M.H. Kollef.
Methicillin-resistant Staphylococcus aureus sterilesite infection: The importance of appropriate initial antimicrobial treatment.
Crit Care Med, 34 (2006), pp. 2069-2074
[12.]
A.F. Shorr, S.T. Micek, M.H. Kollef.
Inappropriate therapy for methicillin- resistant Staphylococcus aureus: resource utilization and cost implications.
Crit Care Med, 36 (2008), pp. 2335-2340
[13.]
J. Edelsberg, A. Berger, D.J. Weber, R. Mallick, A. Kuznik, G. Oster.
Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections.
Infect Control Hosp Epidemiol, 29 (2008), pp. 160-169
[14.]
J.K. Johnson, T. Khoie, S. Shurland, K. Kreisel, O.C. Stine, M.C. Roghmann.
Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 Clone.
Emerg Infect Dis, 13 (2007), pp. 1195-1200
[15.]
E. Cercenado, E. Ruiz de Gopegui.
Staphylococcus aureus resistente a la meticilina de origen comunitario.
Enferm Infecc Microbiol Clin, 26 (2008), pp. 19-24
[16.]
A. Broseta, F. Chaves, P. Rojo, J.R. Otero.
Emergencia de un clon de Staphylococcus aureus resistente a meticilina de origen comunitario en la población pediátrica del sur de Madrid.
Enferm Infecc Microbiol Clin, 24 (2006), pp. 31-35
[17.]
A. Manzur, A.M. Domínguez, M. Pujol, M.P. González, E. Limón, A. Hornero, et al.
Community-acquired methicillin-resistant Staphylococcus aureus infections: an emerging threat in Spain.
Clin Microbiol Infect, 14 (2008), pp. 377-380
[18.]
N. Cobos-Triguero, C. Pitart, F. Marco, J.A. Martínez, M. Almela, J. López, et al.
Epidemiología y forma de presentación clínica de las infecciones originadas por Staphylococcus aureus resistente a meticilina productor de leucocidina de Panton-Valentine.
Rev Esp Quimioter, 23 (2010), pp. 93-99
[19.]
S. Boyle-Vavra, R.S. Daum.
Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin.
Laboratory Investigation, 87 (2007), pp. 3-9
[20.]
O. Cuevas, E. Cercenado, M.J. Goyanes, A. Vindel, P. Trincado, T. Boquete, et al.
Grupo Español para el Estudio de Estafilococo. Staphylococcus spp. en España: situación actual y evolución de la resistencia a antimicrobianos (1986–2006).
Enferm Infecc Microbiol Clin, 26 (2008), pp. 269-277
[22.]
B.P. Howden, P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, P. Du Cros, et al.
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
Clin Infect Dis, 38 (2004), pp. 521-528
[23.]
G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering Jr., G.M. Eliopoulos.
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.
J Clin Microbiol, 42 (2004), pp. 2398-2402
[24.]
M.M. Traczewski, B.D. Katz, J.N. Steenbergen, S.D. Brown.
Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.
Antimicrob Agents Chemother, 53 (2009), pp. 1735-1738
[25.]
G. Steinkraus, R. White, L. Friedrich.
Vancomycin MIC creep in non-vancomycinintermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
J Antimicrob Agents, 60 (2007), pp. 788-794
[26.]
A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, V.P. Dimova, et al.
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia.
Clin Infect Dis, 46 (2008), pp. 193-200
[27.]
J.B. Locke, J. Finn, M. Hilgers, G. Morales, S. Rahawi, G.C. Kedar, et al.
Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.
Antimicrob Agents Chemother, 54 (2010), pp. 5337-5343
[28.]
G. Morales, J.J. Picazo, E. Baos, F.J. Candel, A. Arribi, B. Peláez, et al.
Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolidresistant Staphylococcus aureus.
Clin Infect Dis, 50 (2010), pp. 821-825
[29.]
M. Sánchez-García, M.A. De la Torre, G. Morales, B. Peláez, M.J. Tolón, S. Domingo, et al.
Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.
JAMA, 303 (2010), pp. 2260-2264
[30.]
L. Friedman, J.D. Alder, J.A. Silverman.
Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.
Antimicrob Agents Chemother, 50 (2006), pp. 2137-2145
[31.]
H.W. Boucher, G. Sakoulas.
Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
Clin Infect Dis, 45 (2007), pp. 601-608
[32.]
S.J. Yang, C.C. Nast, N.N. Mishra, M.R. Yeaman, P.D. Fey, A.S. Bayer.
Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
Antimicrob Agents Chemother, 54 (2010), pp. 3079-3085
[33.]
A. Rubio, M. Conrad, R.J. Haselbeck, G.C. Kedar, V. Brown-Driver, J. Finn, et al.
Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycinresistant isolates of Staphylococcus aureus.
Antimicrob Agents Chemother, 55 (2011), pp. 364-367
[34.]
S.J. Van Hal, D.L. Paterson, I.B. Gosbell.
Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycinnaïve patient—a review of the literature.
Eur J Clin Microbiol Infect Dis, 30 (2011), pp. 603-610
[35.]
M.J. Rybak, E. Hershberger, T. Moldovan, R.G. Grucz.
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains.
Antimicrob Agents Chemother, 44 (2000), pp. 1062-1066
[36.]
Y.T. Huang, C.H. Liao, L.J. Teng, P.R. Hsueh.
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Clin Microbiol Infect, 14 (2008), pp. 124-129
[37.]
P.C. Fuchs, A.L. Barry, S.D. Brown.
In vitro bactericidal activity of daptomycin against staphylococci.
J Antimicrob Chemother, 49 (2002), pp. 467-470
[38.]
E. Loza, M.I. Morosini, A. Pascual, F. Tubau, J. Alcalá, J. Liñares, et al.
Actividad comparativa de daptomicina frente a microorganismos grampositivos: programa SENTRY España (2002–2006).
Enferm Infecc Microbiol Clin, 26 (2008), pp. 489-494
[39.]
J.J. Picazo, C. Betriu, E. Culebras, I. Rodríguez-Avial, M. Gómez, F. López, the VIRA Study Group.
Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centres.
Diagn Microbiol Infect Dis, 64 (2009), pp. 448-451
[40.]
J.J. Picazo, C. Betriu, I. Rodríguez-Avial, E. Culebras, F. López, M. Gómez, V.I.R.A. Grupo.
Actividad comparativa de la daptomicina frente a Staphylococcus aureus resistente a meticilina y frente a estafilococos coagulasa negativa.
Enferm Infec Microbiol Clin, 28 (2010), pp. 13-16
[41.]
N. Cotroneo, R. Harris, N. Perlmutter, T. Beveridge, J.A. Silverman.
Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
Antimicrob Agents Chemother, 52 (2008), pp. 2223-2225
[42.]
B.K. English, E.M. Maryniw, A.J. Talati, E.A. Meals.
Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin.
Antimicrob Agents Chemother, 50 (2006), pp. 2225-2227
[43.]
K.C. Lamp, M.J. Rybak, E.M. Bailey, G.W. Kaatz.
In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.
Antimicrob Agents Chemother, 36 (1992), pp. 2709-2714
[44.]
C.T.M. Mascio, J.D. Alder, J.A. Silverman.
Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
Antimicrob Agents Chemother, 51 (2007), pp. 4255-4260
[45.]
K. Smith, A. Pérez, G. Ramage, C.G. Gemmell, S. Lang.
Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin.
Int J Antimicrob Agents, 33 (2009), pp. 374-378
[46.]
J. Parra-Ruiz, C. Vidaillac, W.E. Rose, M.J. Rybak.
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
Antimicrob Agents Chemother, 54 (2010), pp. 4329-4334
[47.]
A.L. Baltch, W.J. Ritz, L.H. Bopp, P. Michelsen, R.P. Smith.
Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
Antimicrob Agents Chemother, 52 (2008), pp. 1829-1833
[48.]
D. Begic, C. Von Eiff, B.T. Tsuji.
Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.
J Antimicrob Chemother, 63 (2009), pp. 977-981
[49.]
R. Wise, T. Gee, J.M. Andrews, B. Dvorchik, G. Marshall.
Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers.
Antimicrob Agents Chemother, 46 (2002), pp. 31-33
[50.]
F. Traunmüller, M.V. Schintler, J. Metzler, S. Spendel, O. Mauric, M. Popovic, et al.
Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.
J Antimicrob Chemother, 65 (2010), pp. 1252-1257
[51.]
B.H. Dvorchik, D. Brazier, M.F. DeBruin, R.D. Arbeit.
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.
Antimicrob Agents Chemother, 47 (2003), pp. 1318-1323
[52.]
R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein.
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis, 38 (2004), pp. 1673-1681
[53.]
J.E. Krige, K. Lindfield, L. Friedrich, C. Otradovec, W.J. Martone, D.E. Katz, et al.
Effectiveness and duration of daptomicyn therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections.
Curr Med Res Opin, 23 (2007), pp. 2147-2156
[54.]
B.A. Lipsky, U. Stoutenburgh.
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.
J Antimicrob Agents, 55 (2005), pp. 240-245
[55.]
R.C. Owens Jr., K.C. Lamp, L.V. Friedrich, R. Russo.
Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Am J Med, 120 (2007), pp. S6-S12
[56.]
B. White, R.A. Seaton.
Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.
Infect Drug Resist, 4 (2011), pp. 115-127
[57.]
S.L. Davis, P.S. McKinnon, L.M. Hall, G. Delgado Jr., W. Rose, R.F. Wilson, et al.
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Pharmacotherapy, 27 (2007), pp. 1611-1618
[58.]
P.E. Pertel, B.I. Eisenstein, A.S. Link, B. Donfrid, E.J.A. Biermann, P. Bernardo, et al.
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erisipelas.
Int J Clin Pract, 63 (2009), pp. 368-375
[59.]
D.E. Katz, K.C. Lindfield, J.N. Steenbergen, D.P. Benziger, K.J. Blackerby, A.G. Knapp, et al.
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
Int J Clin Pract, 62 (2008), pp. 1304-1305
[60.]
R.S. Chamberlain, D.L. Culshaw, B.J. Donovan, K.C. Lamp.
Daptomycin for the treatment of surgical site infections.
Surgery, 146 (2009), pp. 316-324
[61.]
A.G. Knapp, R.K. Kamepalli, W.J. Martone, S. Yankelev.
Prospective, noncomparative study of daptomycin for the treatment of superficial and deep incisional surgical site infections.
Surg Infect (Larchmt), 12 (2011), pp. 113-118
[62.]
I.A. Bliziotis, E. Plessa, G. Peppas, M.E. Falagas.
Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis.
Ann Pharmacother, 44 (2010), pp. 97-106
[63.]
J.F. Logman, J. Stephens, B. Heeg, S. Haider, J. Cappelleri, D. Nathwani, et al.
Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
Curr Med Res Opin, 26 (2010), pp. 1565-1578
[64.]
R.S. Quist, G. Fierlbeck, R.A. Seaton, J. Loeffler, R.I. Chaves.
Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
Intern J Antimicrob Agents, 39 (2012), pp. 90-91
Copyright © 2012. Elsevier España S.L.. Todos los derechos reservados
